Heterogeneity of the immunopathology in advanced multiple sclerosis
An autopsy cohort analysis
Fransen, N.L.

Publication date
2021

Citation for published version (APA):
Absence of B cells in brainstem and white matter lesions associates with a less severe disease and absence of oligoclonal bands in multiple sclerosis

Nina L. Fransen¹, Brigit A. de Jong², Katharina Heß³, Tanja Kuhlmann³, Maria C.J. Vincenten¹, Jörg Hamann¹,⁴, Inge Huitinga¹,⁵, Joost Smolders¹,⁶ *

¹ Department of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, The Netherlands
² Department of Neurology and MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
³ Institute for Neuropathology, University Hospital Münster, Münster, Germany
⁴ Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
⁵ Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
⁶ MS Center ErasMS, departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands

* Equal contribution

Neurol Neuroimmunol Neuroinflamm. 2021 Mar; 8(2): e955
ABSTRACT

Objective | To determine whether B-cell presence in brainstem and white matter (WM) lesions is associated with poorer pathological and clinical characteristics in advanced multiple sclerosis (MS) autopsy cases.

Methods | Autopsy tissue of 140 MS and 24 control cases and biopsy tissue of 24 MS patients was examined for CD20⁺ B cells and CD138⁺ plasma cells. Presence of these cells was compared to pathological and clinical characteristics. In corresponding cerebrospinal fluid (CSF) and plasma, immunoglobulin (Ig)G ratio and oligoclonal band (OCB) patterns were determined. In a clinical cohort of 73 patients, the presence of OCBs was determined at diagnosis and during follow-up.

Results | In 34% of active and 71% of mixed active/inactive lesions, B cells were absent, which correlated with less pronounced meningeal B-cell infiltration (p<0.0001). Absence of B cells and plasma cells in brainstem and WM lesions was associated with a longer disease duration (p=0.001), less frequent secondary progressive MS compared to relapsing and primary progressive MS (p<0.0001 and p=0.046 respectively), a lower proportion of mixed active/inactive lesions (p=0.01) and a trend for a lower number of T cells in MS WM lesions. Moreover, a lower CSF IgG ratio (p=0.006) and more frequent absence of OCBs (p<0.0001) were noted. In a clinical cohort, numbers of patients without OCBs in CSF were increased at follow-up (27.4%).

Conclusions | Absence of B cells is associated with a favorable clinical and pathological profile. This finding may reflect extremes of a continuum of genetic or environmental constitution, but also a regression of WM humoral immunopathology in the natural course of advanced MS.
INTRODUCTION

Multiple sclerosis (MS) is a heterogeneous disease differing in clinical disease course, radiological appearance of the lesions, and response to immunomodulatory therapies. Interestingly, variability between MS patients is observed in the involvement of humoral immunity in the disease. At time of diagnosis, 10% of MS patients show absence of oligoclonal bands (OCBs) consisting of intrathecally produced immunoglobulin (Ig)Gs. Absence of OCBs is associated with a decreased number of lesions on magnetic resonance imaging (MRI) and a more benign disease course. Furthermore, the presence of OCBs in patients with clinically isolated syndrome is associated with an increased risk for clinically definite MS and with a increased risk of disability progression.

In contrast to its limited presence in early MS, advanced progressive MS is characterized by extensive cortical demyelination. Active cortical demyelination is observed in conjunction with the presence of meningeal follicle-like inflammatory structures. The distinct zones of B cells, plasma cells, and T cells resemble tertiary lymphoid structures. The presence of these follicle-like structures associate with more severe disease, reflected by an earlier disease onset and faster accumulation of disability and earlier death. Recently, Reali et al. reported that the density of meningeal B cells correlates with extensive axonal loss and white matter (WM) lesion area, but also with density of B cells in WM perivascular space.

Besides cortical demyelination, demyelinating WM lesions also add up to disease severity in donors with advanced MS. In MS-autopsy cases, the presence of active and mixed active/inactive lesions has been reported to be substantial and correlate with a short time to reaching EDSS-endpoints, a shorter time to death, an unfavorable profile of risk factors for adverse outcomes, and an unfavorable profile of genetic risk factors for adverse outcomes. Furthermore, we showed these active lesions to be populated by infiltrating T cells with a dominant tissue-resident memory T cell fraction showing signs of recent re-activation. Frischer et al. quantified the presence of B cells in MS WM lesion and found these to be predominantly present in perivascular cuffs and meninges, and less frequently in the parenchyma. Presence of B cells was found most frequent in acute lesions in relapsing-remitting donors and less frequently in progressive patients. IgG-producing cells and IgG deposits are regularly found in MS WM lesions. Furthermore, the number of B cells reported in late MS-autopsy lesions is highly variable between cases.

The correlation of B-cell presence in WM lesions with clinical endpoints and risk-factors as well as with meningeal B cell-infiltration has been limitedly explored. Here we investigated the clinical and pathological characteristics of Netherlands Brain Bank (NBB) MS-autopsy cases in association with B-cell infiltration of brainstem and subcortical WM lesions.
MATERIAL AND METHODS

Donor and sample characteristics
141 MS-brain donors and 24 non-neurological controls from the NBB-autopsy cohort (Amsterdam, The Netherlands) were included for the analysis of B cells and plasma cells. Donors came to autopsy between 1991 and 2015, and were diagnosed with MS according to the then diagnostic criteria by their treating physicians. Clinical files were collected post-mortem by the NBB. By retrospective chart analysis, the clinical diagnosis of MS was confirmed for all patients, and the clinical course was defined as either relapsing–remitting (RR), secondary progressive (SP), or primary progressive (PP) by a neurologist. No MRI data were available. None of the donors received MS disease-modifying therapies in the year before autopsy, except for one (B cell-positive) donor on fingolimod. Detailed donor and tissue characteristics are described in Suppl. Table 1, and treatment status is provided in Suppl. Table 2. The pathological diagnosis of MS was confirmed for all cases by a certified neuropathologist. All donors were analyzed for anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin (AQP)4 antibodies using cell-based assays (Suppl. Figure 1).

For the immunohistochemical part of this study, three types of tissues were analyzed for the presence of B cells and plasma cells: (1) standardly dissected tissue blocks at the level of the medulla oblongata (MO) from 140 MS autopsy cases, (2) subcortical WM lesions from 73/140 MS-autopsy cases (158 WM lesions with a median two lesions per donor for both the donors with and without B cells) and 24 non-neurological control donors, and (3) early MS-biopsy WM lesions (N=28) from 24 MS patients, to explore how findings in post-mortem autopsy samples of donors with advanced MS correlate with findings at the earliest stages of MS. These sections were made available by the Institute for Neuropathology, University Hospital Münster (Münster, Germany). Additional information on the analysis and selection of the different tissue samples is described in the Supplementary Methods.

A CSF sample was acquired with a lumbar puncture from 73 MS patients with average disease duration of 11.7 ± 8.5 (mean ± SD) years. These patients visited the MS Center Amsterdam (Amsterdam, The Netherlands) for analysis of cognitive complaints, which is a common symptom in MS. Information on OCB pattern at time of diagnosis was collected by a retrospective chart analysis. Patients characteristics are provided in Table 1.

Standard protocol approvals, registrations, and patient consents
Informed consent was given by the donors of the Netherlands Brain Bank for brain autopsy and for the use of material and clinical data for research purposes. NBB autopsy procedures have been approved by the medical ethics committee of Amsterdam UMC, location VUmc, Amsterdam, The Netherlands. Sampling of biopsies and CSF has been approved by the medical ethics committee of the University Hospital Münster and Amsterdam UMC, location VUmc, respectively.
Immunohistochemistry

Immunohistochemistry of the autopsy tissue samples was performed on 8-μm thick formalin-fixed paraffin-embedded tissue sections. All brainstem and subcortical WM tissue sections were immunostained for myelin (proteolipid protein, PLP) and human leukocyte antigen (HLA-DR/DQ, referred to as HLA) as previously described. Lesions were annotated and sections were stained for CD20, CD138, and CD3 as described in the Supplementary Methods. For CD138, an image of the positive control in tonsil is provided in Suppl. Figure 2.

OCB and IgG measurement in CSF and plasma

A selection of 16 NBB MS cases without presence of B cells and CD138+ plasma cells in perivascular space and parenchyma of both MO and subcortical active WM lesions and 16 MS cases with B cells and CD138+ plasma cells at these locations was made to analyze post-mortem cerebrospinal fluid (CSF) samples. One case was excluded due to CSF anti-MOG positivity (Suppl. Figure 1). Paired plasma samples were available from 20 of these MS autopsy cases (10 with B cells and 10 without B cells). Additionally, paired CSF and serum samples of 73 MS patients were analyzed. In all samples, IgG levels were determined with nephelometry, and the presence of OCBs was analyzed with isoelectric focusing followed by IgG immunoblotting.

Statistical analysis

Statistical analysis were performed in GraphPad Prism 8 (8.1.1, April 2019; GraphPad, San Diego, CA, USA). Proportional differences between two or more strata were tested with the Fisher’s exact and Chi-Square test, respectively. Brainstem lesion load and reactive site load were log transformed. Normally distributed data were analyzed using a Students t-test. Non-parametric Mann–Whitney U test was used when data was not normally distributed data. For disease duration and age at death a survival, analysis was performed using the Gehan–Breslow–Wilcoxon test.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

RESULTS

B cells are present in early-MS biopsy lesions and in active and mixed active/inactive MS-autopsy lesions

Of the NBB MS autopsy cohort, we analyzed the material of N=140 donors for the current study. First, we analyzed the presence of B cells and CD138+ plasma cells in the MO, since this is one of the few standardly-dissected regions in the NBB MS-autopsy protocol, which contains both WM and grey matter (GM) brain parenchyma and meninges. B cells were more often present in the perivascular space (p<0.004) and meninges (p<0.0001), compared to the brain parenchyma (17%,
51%, and 4% of cases, respectively Figure 1A-B). In the MO collection, 85 sections contained MS lesions, and 53 sections did not contain MS lesions. B cells and CD138+ plasma cells were found more frequently (p=0.028 and p=0.038, respectively) in sections with MS lesions (21% had B cells and 19% had plasma cells), compared to normal-appearing MO tissue sections (9% had B cells and 8% had plasma cells) (Figure 1C-D).

To investigate the association with WM lesion characteristics, we scored the presence of B cells and CD138+ plasma cells in subcortical WM from 24 non-neurological controls and 73 MS-autopsy cases, containing 158 MS lesions (10 reactive, 41 active, 66 mixed active/inactive, 25 inactive, and 16 remyelinated). Moreover, we determined the presence of B cells and CD138+ plasma cells in 28 early MS biopsies from WM lesions, which were all active. In the non-neurological controls, we identified B cells (2-5 cells per section) in the meninges in 4% (2 out of 24) of the cases. B cells were more frequently found in early biopsy (93%; p<0.0001) and in active (66%; p<0.0001) and mixed active/inactive (29%; p<0.0001) autopsy MS lesions compared to control WM. Notably, in 34% of the active autopsy lesions, no B cells were identified. In reactive (10%), inactive (8%), and remyelinated lesions (6%), B cells were not significantly enriched, compared to control WM (Figure 1E). In control WM and meninges, no CD138+ plasma cells were identified. CD138+ plasma cells were found in early biopsy lesions (56%; p=0.004) and in all autopsy MS-lesion subtypes – reactive (10%; p=0.002), active (22%; p<0.0001), mixed active/inactive (8%; p=0.007), inactive (24%; p<0.0001), remyelinated (19%; p<0.0001), compared to control WM (Figure 1F-I).

The presence of B cells and CD138+ plasma cells is a general donor characteristic.

We next assessed the presence of B cells and CD138+ plasma cells within multiple locations (parenchyma, perivascular space, and meninges) and tissue blocks (MO and subcortical WM) from the same donors (Figure 2A-B). The presence of B cells in the perivascular space was associated with the presence of B cells in the meninges (92% and 43% in donors with and without perivascular B cells, respectively; p<0.0001; Figure 2D). This is in accordance with Reali et al., who also observed a positive correlation between B-cell counts in meninges and perivascular space of MS spinal cords.14 Furthermore, the presence of B cells in the MO was associated with the presence of B cells in subcortical WM (50% and 27% in donors with and without MO B cells, respectively; p=0.001; Figure 2E).

Limited presence of B cells in MS-autopsy cases associates with a favorable clinical and pathological profile.

To assess whether the presence of B and CD138+ plasma cells in MO and subcortical WM lesions correlates with more severe MS, likewise earlier reported for meningeal B-cell infiltrates, we compared donors with and without B cells at these locations. B cells were frequently encountered in perivascular clusters with T cells (Figure 3A). Cases without B cells at the MO showed less often perivascular cuffing of T cells in the MO (11% and 35%; p<0.0001, Figure 3B). Cases without B cells in subcortical WM showed a trend for a lower number of T cells in subcortical MS lesions (median
Figure 1. B cells are enriched in biopsy lesions and active and mixed active/inactive lesions at autopsy. 
(A/B) B cells and plasma cells were enriched in perivascular space and meninges of the MO, compared to 
MO parenchyma. (C/D) MO lesions contained more frequently B cells and plasma cells, compared to the 
normal-appearing MO (NA MO). MS lesion subtypes were analyzed in the subcortical WM. (E) Early MS 
biopsy lesions significantly more often contained B cells, compared to all autopsy lesions. In active and mixed 
active/inactive autopsy lesions, B cells were significantly more often present, compared to control WM. (F) 
Early MS-biopsy lesions significantly more often contained plasma cells, compared to autopsy lesions. Plasma 
cells were significantly more often present in all MS lesion types, compared to control WM. (G) Example of 
an inflammatory active MS lesions of a secondary progressive MS brain donor with MS for 27 years, stained 
for HLA (black) and PLP (brown). Scale bar is 500 µm. (H/I) In the perivascular space, B cells (CD20⁺, panel H, 
scale bar is 50 µm) and a plasma cell (CD138⁺, panel I, scale bar is 25 µm) were present (both brown color). 
* p<0.05, ** p<0.01, and **** p<0.0001.
Figure 2. B-cell and plasma cell presence in meninges and perivascular space is consistent within donors.

(A) In the MO of donor 1 with 27 years of secondary progressive MS, B-cell and plasma cell infiltrates were identified in both the perivascular space (PVS) and meninges (M). Scale bars are 100 µm for CD20 and 50 µm for CD138. (B) In the MO of donor 2 with a primary progressive disease course and a disease duration of 2 years, B cells were detected in the perivascular space but not in the meninges, and no plasma cells were identified. Scale bars are 50 µm for CD20 and CD138 in PVS and 100 µm for CD20 in meninges. (C) In the MO of donor 3 with a relapsing disease course for 38 years, no B cells or plasma cells were identified in both the meninges and perivascular space. Scale bars are as in A. (D) The absence of B cells in the perivascular space (PVS) is associated with the absence of B cells in the meninges. (E) The absence of B cells in the MO is associated with the absence of B cells in subcortical WM. **p<0.01, ****p<0.0001.
Figure 3. MS cases with limited presence of B cells show a favorable pathological and clinical profile. (A) B cells were often encountered in perivascular clusters together with T cells. Scale bars are 100 µm. (B) MS cases with limited presence of B cells showed less often perivascular clustering of CD3+ T cells, (C) a trend for a lower number of CD3+ T cells in MS lesions, (D) a lower percentage of mA/I lesions, (E) a higher age at death, (F) a longer disease duration, and (G) more often a secondary progressive disease course. * p < 0.05, *** p < 0.001, **** p < 0.0001.
3.3 vs 8.3 cells/mm^2; \( p=0.06 \); Figure 3C) and a lower overall percentage of mixed active/inactive lesions (mean 23.7% vs 39.6%; \( p=0.01 \); Figure 3D), compared to MS donors with B cells. Clinically, they showed a higher age at death (median 69.0 vs 55.5; \( p=0.0006 \); Figure 3E) and a less severe clinical disease course, defined as a longer disease duration (median 31.0 vs 22.0; \( p=0.007 \); Figure 3F), and they more often had a persistent relapsing or primary progressive course, compared to a secondary progressive course (100% and 87% vs 75%; \( p<0.0001 \) and \( p=0.046 \); Figure 3G). There was no difference in brainstem lesion load, reactive site load, percentage of inactive remyelinated areas, and incidence of cortical GM lesions between MS cases with and without B cells at the investigated locations (Suppl. Figure 3).

MS autopsy cases with limited presence of B cells show a lower intrathecal IgG production and lack more often OCBs

Since our data suggest an association between the presence of B cells in meninges and MO/subcortical WM, as well as an association with a more severe pathological and clinical profile, we explored its relevance for intrathecal B-cell activation. Since an increased intrathecal IgG production and OCB presence are highly correlating biomarkers of MS,31 and presence of OCB’s is associated with adverse outcomes,6,32 we explored whether these CSF biomarkers were associated with B-cell and CD138*-plasma cell presence in MO and subcortical WM lesions. We conducted an extreme-of-outcomes-analysis by selecting 16 cases with B cells and 16 cases without B cells and CD138+ plasma cells in both MO and subcortical WM lesions. One MS case with B cells and CD138+ plasma cells was excluded prior to OCB analysis since anti-MOG antibodies were detected in the post-mortem CSF. There was no significant association of IgG index and OCB presence (Figure 4A) with post-mortem delay. The pH of post-mortem CSF showed a positive correlation with IgG index (Spearman’s correlation \( R=0.498; p=0.035 \)), but not with OCB presence of presence of B cells (Suppl. Figure 4). Selected cases lacking B cells and CD138+ plasma cells in MO and subcortical WM lesions showed a lower CSF IgG level (median 0.04 vs 0.07; \( p=0.02 \), Figure 4B) and a lower IgG CSF/serum ratio (median 0.003 vs 0.008; \( p=0.007 \), Figure 4C), indicating a lower intrathecal IgG production compared to MS cases with B cells. CSF OCBs were absent in 37% of cases without B cells and CD138+ plasma cells, while all cases with B cells displayed CSF OCBs (\( p<0.0001 \); Figure 4D). This observation suggests that these MS cases with limited presence of B cells and CD138+ plasma cells in MO and subcortical WM lesions are characterized by an overall altered CSF IgG clonality and lower IgG production. This observation is again in line with the strong correlation reported by Reali et al. between meningeal and perivascular B-cell presence.14 Additionally, the IgG index, but not the presence of OCBs, was positively correlated with the number of T cells in subcortical WM (Suppl. Figure 5A). Other pathological endpoints did not correlate with IgG production or clonality (Suppl. Figure 5B-D).

OCBs can disappear over time in MS patients

In MS autopsy cases selected for absence of B cells and CD138+ plasma cells, the prevalence of OCBs was lower than the expected 90% OCB-positivity of MS patients at diagnosis.33 This difference
Figure 4. MS cases with limited B cells show lower intrathecal IgG-production and more often lack OCBs.

(A) Example of OCB-patterns in paired CSF and plasma for a donor without (donor 1) and a donor with (donor 2) CSF-unique OCBs. MS cases with limited presence of B cells show (B) a lower concentration of IgG in post-mortem CSF and (C) a lower CSF/plasma IgG ratio, suggesting a lower intrathecal IgG production, and (D) more lack CSF OCBs. * p<0.05, ** p<0.01, **** p<0.0001.
Table 1. Clinical cohort of MS patients with OCB examinations.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Cases (n (%))</th>
<th>Age at OCB (years)</th>
<th>Sex</th>
<th>MS type (%)</th>
<th>Disease duration at OCB (years)</th>
<th>Treatment (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All MS</strong></td>
<td>73</td>
<td>49.2 ± 10.0</td>
<td>46F/27M</td>
<td>RR 68</td>
<td>11.7 ± 8.5</td>
<td>49 DMT 51 none</td>
</tr>
<tr>
<td><strong>OCB-positive</strong></td>
<td>53 (72.6)</td>
<td>48.3 ± 9.7</td>
<td>32F/21M</td>
<td>RR 75</td>
<td>11.4 ± 8.5</td>
<td>53 DMT 47 none</td>
</tr>
<tr>
<td><strong>OCB-negative</strong></td>
<td>20 (27.4)</td>
<td>51.5 ± 10.7</td>
<td>14F/6M</td>
<td>RR 55</td>
<td>13.2 ± 8.7</td>
<td>40 DMT 60 none</td>
</tr>
</tbody>
</table>

**All OCB-negative**

| At diagnosis OCB-positive        | 6 (30)        | 49.5 ± 9.7         | 5F/1M        | BD 17       | 11.0 ± 7.0                     | 83 DMT 17 none|
| Previously elevated IgG, OCB unknown | 4 (20)      | 60.0 ± 9.6         | 2F/2M        | CIS 25      | 17.3 ± 5.7                     | 25 DMT 75 none|
| At diagnosis OCB-negative        | 4 (20)        | 49.0 ± 10.6        | 3F/1M        | CIS 50      | 6.0 ± 9.4                      | 25 DMT 75 none|
| Not reported                     | 6 (30)        | 49.5 ± 12.1        | 4F/2M        | RR 50       | 16.0 ± 10.1                    | 17 DMT 83 none|

**OCB-negative, at diagnosis positive**

| Case 1                           | 56            | F                  | RR           | 20          | GLA                            |
| Case 2                           | 54            | F                  | RR           | 8           | DMF                            |
| Case 3                           | 37            | F                  | RR           | 13          | DMF                            |
| Case 4                           | 52            | F                  | BD           | 4           | IFNβ                           |
| Case 5                           | 38            | F                  | RR           | 2           | DMF                            |
| Case 6                           | 60            | M                  | SP           | 16          | none                           |

Provided is the mean ± SD (standard deviation). BD, Balo’s disease; CIS, clinically isolated syndrome; DMF, dimethyl fumarate; F, female; GLA, glatiramer acetate; IFNβ, interferon-β; M, male; NR, not reported; PP, primary progressive; RR, relapsing–remitting; SP, secondary progressive; various, BD, CIS and, NR.

could be explained by selection of MS donors with an extreme profile of genetic or environmental factors, but also by a decline of the intrathecal humoral immune response overtime in chronic MS. In our current study, two of six MS cases without OCBs at autopsy had an elevated IgG ratio at diagnosis without information on OCBs, one of six donors had normal diagnostic CSF examination, and no information was available for the three other donors. To explore whether a dynamic course of OCB pattern throughout the disease course of MS can be a plausible explanation of our findings,
the presence of OCBs was determined in a clinical cohort of 73 MS patients that underwent a lumbar puncture after an average disease duration of 11.7 ± 8.5 (mean ± SD) years. In 27.4% (20 out of 73) of the MS patients, OCBs were absent. In six of the 20 MS patients without OCBs at follow-up, OCBs were present at time of diagnosis (Table 1). Although laboratory differences can be confounders, these data support the hypothesis that the contribution of B cells to MS pathology may decline during the course of MS.

DISCUSSION

We here demonstrate absence of B cells and CD138⁺ plasma cells in 34% of the active WM lesions of advanced MS cases in the NBB autopsy cohort. Cases without B cells at MO or subcortical WM showed a more favorable pathological profile as indicated by a lower number of T cells in MS lesions, a lesser frequency of perivascular cuffing of T cells, and a lower percentage of mixed active/inactive lesions. Clinically, they manifested with a less frequent secondary progressive disease course, a longer disease duration, and a lower percentage of mixed active/inactive lesions, compared to the MS donors with B cells in MO or subcortical WM lesions. Further, a selected subgroup of MS patients without WM B cells and CD138⁺ plasma cells had a lower intrathecal IgG production and lacked more often unique OCBs in post-mortem CSF. Our findings indicate that, besides an important role of meningeal B cells in cortical pathology of advanced progressive MS, B-cell infiltration in WM is also a detrimental phenomenon at the later stages of MS.

In MS and also other autoimmune diseases, B cells have been described to play an important role in antigen presentation and cytokine production, which induces the activation and proliferation of T cells. MS cases with B cells show an increased number of T cells in their MS lesions suggesting increased T-cell activation. We and others previously showed that re-activated tissue resident-memory T cells (T_{RM}) are associated with the ongoing inflammatory lesion activity in WM lesions from advanced MS cases. In MS lesions, these re-activated T_{RM} cells are often encountered in clusters in the perivascular space together with B cells suggesting that antigen presentation and reactivation of T_{RM} cells induced by B cells potentially occurs at this location. This illustrates that besides IgG production, B cells may have different functional roles in MS WM lesions.

We show that CD138⁺ plasma cells are present more often in MS lesions compared to control and normal-appearing WM in line with earlier reports, however, only in a low percentage of the MS autopsy cases. Interestingly, CD138⁺ plasma cells were most often present in inactive lesions compared to the other lesion subtypes. Prineas et al. previously showed in a detailed electron microscopy study of the perivascular space in MS tissues that high numbers of plasma cells are present in inactive lesion areas. This suggests that CD138⁺ plasma cells play a less prominent role compared to B cells in the ongoing microglial activity of MS lesions. Ocrelizumab and rituximab, which show an effect on disease progression in MS, are directed against circulating CD20⁺ B cells but do not affect CD138⁺ plasma cells.
A large heterogeneity in the number of B cells and the presence of IgG depositions in MS lesions has been described over the past decades. In both, early MS biopsies as well as late MS autopsies, the presence and absence of IgG deposits in MS lesions has been described. Also the number of B cells in MS autopsy lesions is highly heterogenuous between MS cases. In 34% of the inflammatory active MS lesions in autopsy tissue, we identified no B cells and we showed that presence of B cells correlates between different location (MO and subcortical WM) and compartments (parenchyma, perivascular space, meninges) in an individual donor.

In a selected subgroup of MS cases without WM B cells, a lower intrathecal IgG production and a more frequent absence of OCBs was found. The presence of OCBs in 60% in these MS cases is lower compared to clinical MS cohorts, where 90% showed OCBs at diagnosis. Possibly, we now selected an extreme subgroup of MS cases with a genetic profile at one side of a continuum that restricts involvement of B cells in MS lesion pathogenesis. Alternatively, since we identified B cells in 92% of the early MS biopsy lesions, and the MS cases with limited B-cell presence in autopsy tissue had a longer disease duration and older age, B-cell involvement in WM lesion activity might be extinguishing over time. Accordingly, Frischer et al. reported higher numbers of perivascular B cells in donors with relapsing and progressive disease, when compared to inactive disease. We provided some support for this hypothesis, by observing in a clinical cohort the absence of OCBs in 27.4% of patients after a disease duration of 11.7 ± 8.5 (mean ± SD) years. In six of these patients without OCBs, their presence at diagnosis could be validated. In four of these patients, the elevated IgG index at diagnosis was validated. These data require careful interpretation, since comparison with historical data on OCB presence may be inaccurate. It is not likely that treatment with disease-modifying therapies confounds these results. In clinical studies, the presence of CSF OCBs was not-affected by highly efficacious therapies as fingolimod, rituximab, and alemtuzumab, while treatment with natalizumab and cladribine was associated with reduced OCBs. Treatment with dimethyl-fumarate has not been associated with lower CSF IgG production. Although loss of CSF OCBs has been described in a cohort of interferon-beta and glatiramer acetate-treated MS patients, this has not been observed in controlled studies. Whether the absence of perivascular B cells truly is a biomarker for the regression of WM inflammatory disease activity in advanced MS remains to be determined. Regarding cessation of disease-modifying therapies in advanced MS, this could be a clinically useful hypothesis to pursue.

Our study has some limitations. Due to the structure of the NBB donor program, we could only investigate presence of B cells at selected locations in WM and meninges. Bias in our data by sample and site selection cannot be excluded, which may be partially overcome by selecting a standardly dissected location and comparing multiple locations within the same donor. The extreme outcome analysis, comparing donors with or without B cells at multiple locations in a dichotomous approach, providing a rather crude estimate of biological associations than correlation analyses. However, due to limited availability of material, this was for the current research question the most feasible approach.
In sum, we here demonstrate in an advanced MS-autopsy cohort that absence of B cells at the MO and subcortical WM is associated with a favorable clinical and pathological profile. This finding may reflect extremes of a continuum of genetic or environmental constitution, but also a regression of WM humoral immunopathology in the natural course of advanced MS.
REFERENCES


SUPPLEMENTARY MATERIAL

Supplementary methods

Sample selection
For the immunohistochemical part of this study, three types of tissues were analyzed:

1. Standardly dissected tissue blocks at the level of the medulla oblongata (MO) were systematically examined for B cells and plasma cells. This approach allowed a standardized comparison between MS cases in the MS-autopsy cohort. The MO was selected since (1) it is one of the few regions standardly and unbiasedly dissected in the NBB-autopsy protocol, (2) it contains white matter, grey matter, and meninges and hereby covers relevant tissue compartments for MS, (3) brainstem lesions as presenting clinical symptom or on MRI scans are associated with a poor prognosis in MS patients and therefore are clinically very relevant to study. MO tissue blocks were obtained from 140 MS donors, and 1 MO tissue section was analyzed per case. B-cell and plasma cell presence or absence was scored for three regions within the MO section: the meninges, the perivascular space, and the parenchyma. B cells and plasma cells were considered present when >1 individual cell could be identified in the section. The scoring was performed by an observer that was blinded for the MS-lesion characterization of these sections. MS cases with B cells in the MO (n=24) were compared to the cases without both B cells and plasma cells in the MO (n=107). MO sections that contained MS lesions and sections without any MS lesions were compared. The presence of infiltrates of B cells was scored separately when clusters of B cells were identified in the perivascular space or the meninges.2–4

2. In addition to the MO, to assess the consistency of findings when sampling tissue at another location, 158 subcortical white matter (WM) lesions from 73 MS cases and subcortical white matter from 24 non-neurological controls was examined for the presence of B cells and plasma cells. The total WM per section was systematically scored, and in all positive sections, the presence of B cells and plasma cells in WM lesions was scored separately for each lesion.

3. To explore how findings in post-mortem autopsy samples of donors with advanced MS correlate with findings at the earliest stages of MS, 28 biopsies of WM lesions from 24 early MS patients were scored for the presence of B cells and plasma cells.

MS lesion characterization
Reactive, active, mixed active/inactive, inactive, and inactive remyelinated lesions were distinguished using HLA and PLP immunohistochemistry as previously described.5,6 In short, reactive sites are characterized by normal-appearing myelin with increased number of activated microglia/macrophages, active lesions show partial loss of myelin with microglia/macrophages throughout the lesion area, mixed active/inactive lesions are characterized by a demyelinated inactive center with a rim of activated microglia/macrophages, and inactive and remyelinated lesions are characterized by partial loss of myelin without any microglia/macrophages. The characterization of MS lesion subtypes in the autopsy lesions is comparable to the characterization performed in the early biopsy lesions according to Kuhlmann et al.7
**Immunohistochemistry**

Lesions were annotated, and adjacent sections were stained for CD20 (M0755, concentration 1:100; Agilent, Santa Clara, CA, USA), CD138 (MCA2459, concentration 1:500; Biorad, Hercules, CA, USA), and CD3 (GA503, concentration 1:100; Agilent) using previously described protocols. \(^6,8\) Biopsy lesions were all characterized as active as described in Kuhlmann et al. \(^7\) For the biopsy lesions, 4-μm thick sections were cut, and immunohistochemistry for CD20 (M0755, concentration 1:700) and CD138 (MCA2459, concentration 1:500) was performed. Images of CD20 and CD138 immunostainings were taken using an Axioscope microscope with a micropublisher 5.0 RTV digital CCD camera (Qimaging, Surrey, BC, Canada) and the Image-Pro Plus 6.3 software (Media Cybernetics, Rockville, MD, USA). The number of T cells in MS lesions and subcortical WM were assessed using black and white images from tissue sections and particle analysis as previously described. \(^8\) Perivascular T-cell cuffing was assessed based on CD3 immunohistochemistry, where cuffing was considered when >1 ring of CD3 \(^+\) cells was present, as previously described in Fransen et al. 2020. \(^8\)

**REFERENCES**

### Supplementary Table 1. Donor and sample information for immunohistochemistry.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Cases (n)</th>
<th>Age (years)</th>
<th>Sex (F/M)</th>
<th>PMD (h:min)</th>
<th>pH value</th>
<th>Brain weight (g)</th>
<th>Disease duration (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>140</td>
<td>64.8 ± 13.0</td>
<td>88/52</td>
<td>9:13 ± 6:40</td>
<td>6.5 ± 0.3</td>
<td>1192.0 ± 135.4</td>
<td>30.1 ± 13.2</td>
</tr>
<tr>
<td>RR</td>
<td>13</td>
<td>64.8 ± 16.0</td>
<td>8/5</td>
<td>11:52 ± 14:12</td>
<td>6.5 ± 0.4</td>
<td>1202.6 ± 102.0</td>
<td>25.8 ± 11.5</td>
</tr>
<tr>
<td>PP</td>
<td>49</td>
<td>67.9 ± 12.8</td>
<td>30/19</td>
<td>8:39 ± 4:32</td>
<td>6.5 ± 0.3</td>
<td>1193.8 ± 132.3</td>
<td>28.6 ± 12.3</td>
</tr>
<tr>
<td>SP</td>
<td>78</td>
<td>62.8 ± 12.3</td>
<td>50/28</td>
<td>9:07 ± 5:53</td>
<td>6.5 ± 0.3</td>
<td>1189.2 ± 143.0</td>
<td>31.8 ± 13.9</td>
</tr>
<tr>
<td>Biopsy MS donors</td>
<td>24</td>
<td>45.0 ± 13.9</td>
<td>18/6</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Non-neurological controls</td>
<td>24</td>
<td>69.0 ± 12.7</td>
<td>13/11</td>
<td>7:53 ± 0:13</td>
<td>6.3 ± 0.3</td>
<td>1264.4 ± 142.6</td>
<td>–</td>
</tr>
</tbody>
</table>

Provided is the mean ± SD (standard deviation). F, female; M, male; PMD, post-mortem delay; PP, primary progressive; RR, relapsing–remitting; SP, secondary progressive.

### Supplementary Table 2. Disease-modifying therapy status of the MS-autopsy cohort.

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Total (n)</th>
<th>B cell positive (%)</th>
<th>B/plasma cell negative (%)</th>
<th>OCB positive (%)</th>
<th>OCB negative (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interferon-beta</td>
<td>25/136 (18)</td>
<td>6/21 (29)</td>
<td>17/106 (16)</td>
<td>5/25 (20)</td>
<td>0/6 (0)</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>1*/136 (0)</td>
<td>0/21 (0)</td>
<td>1/106 (1)</td>
<td>1/25 (4)</td>
<td>0/6 (0)</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>2*/136 (1)</td>
<td>1/21 (5)</td>
<td>1/106 (1)</td>
<td>2/25 (8)</td>
<td>0/6 (0)</td>
</tr>
<tr>
<td>Glatiramer acetate</td>
<td>3/136 (2)</td>
<td>0/21 (0)</td>
<td>2/106 (2)</td>
<td>1/25 (4)</td>
<td>0/6 (0)</td>
</tr>
</tbody>
</table>

Of 4 MS autopsy cases included in the study, no information on therapy status could be obtained from the clinical files. B-cell and plasma cell status was obtained at the standardized location of the MO.

*One B cell-negative patient was treated with natalizumab 9 years before death and switched to fingolimod 3 years before death, with discontinuation of treatment 1 year prior to death. One B cell-positive patient received DMT (fingolimod) 1 year before death. All other patients did not receive therapy in the year before death.
Supplementary Figure 1. Flowchart of donor and sample inclusion.
Supplementary Figure 2. Control staining of tonsil tissue for CD138+ plasma cells (scale bar is 25 μm).
Supplementary Figure 3. Pathological parameters that were not significantly different between MS cases with and without B cells.

(A) Number of lesions in the brainstem, (B) Number of reactive sites in the brainstem, (C) Percentage of remyelinated areas, and (D) Incidence of cortical grey matter (GM) lesions.
Supplementary Figure 4. Correlation of post-mortem delay (PMD, left column) and CSF pH (right column). With (A,B) IgG index, (C,D) presence of OCB in the post-mortem CSF samples, and (E,F) presence of B cells in the MO.
Supplementary Figure 5. Association of (A,B) IgG index and (C,D) OCB presence with (A,C) number of T cells in subcortical white matter and (B,D) the percentage of mixed active/inactive (mA/I) lesions.